CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Tafinlar & Mekinist in combo for Metastatic Melanoma - Details

Project Number PC0053-000
Brand Name Tafinlar & Mekinist in combo
Generic Name Dabrafenib & Trametinib in combo
Strength Dabrafenib: 50mg and 75mg capsules;Trametinib: 0.5mg and 2.0mg tablets
Tumour Type Skin and Melanoma
Indication Metastatic Melanoma
Funding Request Dabrafenib and trametinib in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF 600 mutation.
Review Status Complete
Pre Noc Submission Yes
NOC Date March 6, 2015
Manufacturer GlaxoSmithKline Inc.
Sponsor GlaxoSmithKline Inc.
Submission Date February 13, 2015
Submission Deemed Complete February 23, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ March 2, 2015
Check-point meeting April 8, 2015
pERC Meeting June 18, 2015
Initial Recommendation Issued July 3, 2015
Feedback Deadline ‡ July 17, 2015
Final Recommendation Issued July 21, 2015
Notification to Implement Issued August 6, 2015
Therapeutic Area Metastatic Melanoma
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.